This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 08/07/2023 12:30 PM

BUY State Bank of India

Margin decelerates, but RoA accelerates >1%

BFSI - Banks > Result Update > August 5, 2023

Notwithstanding the slower growth and sharp margin contraction, SBI continued to deliver a strong PAT beat, at Rs168bn (Emkay: Rs149bn)/1.2% RoA in 1Q, on robust treasury gains, lower overheads and LLP. Though NIM contraction for SBI in 1Q was relatively higher (27bps QoQ to 3.3%) vs private peers (12-20bps), we believe most banks on cumulative basis would in near term will exhibit similar margin contraction. Bank guides for 13-14% growth in FY24E led by Retail which, along with better LDR/consumption of on-balance-sheet liquidity, should help sustain FY24E margin at 3.4-3.5% (reported). Despite the lower CET 1 at 10.2%, Bank believes that it can fund current growth via internal accruals.

Factoring-in the 1Q beat, we raise our earnings by 2-3% for FY24-26E and expect the bank to deliver a healthy 1-1.1% RoA/17-19% RoE without any capital raise. We retain BUY on the stock with TP of Rs700/share, valuing the standalone bank at 1.2x Jun-25E ABV and subs/investments at Rs185/share.

| State Bank of India: | Financial S | Snapshot (S | tandalone) | | |
|-------------------------|--------------------|-------------|------------|---------|---------|
| Y/E Mar (Rs mn) | FY22 | FY23 | FY24E | FY25E | FY26E |
| Net profit | 390,943 | 502,325 | 620,720 | 667,687 | 715,389 |
| Loan growth (%) | 11.6 | 17.0 | 13.1 | 14.4 | 16.0 |
| NII growth (%) | 9.0 | 20.0 | 12.4 | 11.0 | 11.1 |
| NIM (%) | 2.8 | 3.0 | 3.0 | 3.0 | 3.0 |
| PPOP growth (%) | 5.2 | 11.2 | 15.3 | 11.8 | 14.9 |
| Adj. EPS (Rs) | 43.8 | 56.3 | 69.6 | 74.8 | 80.2 |
| Adj. EPS growth (%) | 91.5 | 28.5 | 23.6 | 7.6 | 7.1 |
| Adj. BV (INR) | 264.2 | 318.0 | 374.6 | 433.3 | 492.0 |
| Adj. BVPS growth (%) | 16.3 | 20.4 | 17.8 | 15.6 | 13.6 |
| RoA (%) | 0.8 | 1.0 | 1.1 | 1.0 | 1.0 |
| RoE (%) | 16.1 | 18.1 | 19.1 | 17.8 | 16.6 |
| P/E (x) | 8.8 | 6.9 | 5.6 | 5.2 | 4.8 |
| P/ABV (x) | 1.6 | 1.3 | 1.1 | 0.9 | 0.8 |

Source: Company, Emkay Research

Slower growth, higher deposit cost led to sharp margin contraction

SBI reported relatively slower growth at 15% YoY/1.1% QoQ vs the system's at 16.2% YoY/5.2% QoQ, mainly due to de-growth in the overseas book amid rising dislocation and muted corporate growth (partly due to pay-off by a large corporate). However, retail growth remains strong at 17% YoY/2% QoQ; within which in Auto, Gold and X-press credit continues to grow at a healthy pace, while mortgages growth was moderate. Deposit growth was largely in line with the system's at 12% YoY/2.4% QoQ, which led to slightly lower LDR at 71%. This, coupled with flattish investment yields and sharp jump in deposit cost, led to a 27bps QoQ contraction in NIM to 3.3%. Going forward, Bank guides for 13-14% credit growth led by retail in FY24E which, along with better LDR/consumption of on-balance-sheet liquidity, should help sustain margins at 3.4-3.5% (reported) in FY24E.

Slippages inch up due to seasonal factors, but NPAs remain stable

Gross slippages were higher (in line with our expectations) at Rs79bn/1.1% of loans (due to higher slippages from Agri at 3.5% and from SME at 2.6%), leading to nearly flat GNPA ratio of 2.8%. However, the bank has already recovered ~21% of the slippages in the Jul-2023 itself which should thus lead to steady reduction in NPAs during 2Q. The restructured pool continued to moderate, to Rs226bn/0.7% of loans vs 0.8% in Q4. On personal loans, the bank allays any asset-quality concerns that it claims are largely (95%) built towards government employees with steady salary flow.

We retain BUY

Factoring-in the 1Q beat, we raise our earnings by 2-3% for FY24-26E and expect the bank to deliver a healthy 1-1.1% RoA/17-19% RoE without any capital raise. We retain BUY on the stock with TP of Rs700/share, valuing the standalone bank at 1.2x Jun-25E ABV and subs/investments at Rs185/share. Despite the lower CET 1 at 10.2%, Bank believes that it can fund the current growth through internal accruals and is thus in no hurry to raise capital. **Key risks:** Severe macro dislocation and a prolonged elevated-rate environment hurting margins, leading to growth/asset quality disruption.



Ticker

TARGET PRICE (Rs): 700

| Target Price – 12M | Jun-24 |
|-----------------------|--------|
| Change in TP (%) | - |
| Current Reco. | BUY |
| Previous Reco. | BUY |
| Upside/(Downside) (%) | 22.1 |
| CMP (04-Aug-23) (Rs) | 573.3 |
| | |

Stock Data

| Stock Data | TICKET |
|-------------------------|-----------|
| 52-week High (Rs) | 630 |
| 52-week Low (Rs) | 499 |
| Shares outstanding (mn) | 8,924.6 |
| Market-cap (Rs bn) | 5,116 |
| Market-cap (USD mn) | 61,763 |
| Net-debt, FY24E (Rs mn) | NA |
| ADTV-3M (mn shares) | 17 |
| ADTV-3M (Rs mn) | 9,983.1 |
| ADTV-3M (USD mn) | 120.5 |
| Free float (%) | 43.0 |
| Nifty-50 | 19,517 |
| INR/USD | 82.8 |
| Shareholding, Jun-23 | |
| Promoters (%) | 56.9 |
| FPIs/MFs (%) | 10.3/24.6 |
| | |

| Price Performance | | | | | | | | | |
|-------------------|-------|-------|-------|--|--|--|--|--|--|
| (%) | 1M | 3M | 12M | | | | | | |
| Absolute | (2.7) | (1.2) | 7.5 | | | | | | |
| Rel. to Nifty | (3.3) | (7.5) | (4.3) | | | | | | |



Anand Dama

anand.dama@emkayglobal.com +91 22 6624 2480


Dixit Sankharva

dixit.sankharva@emkayglobal.com +91 22 6612 1281

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 08/07/2023 12:30 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAYsGO>Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.


Story in Charts

Exhibit 1: Credit growth moderates to 15% vs systemic credit growth at 16%




Source: Company, Emkay Research

Exhibit 3: CASA cannibalization leads to moderation in CASA ratio




Source: Company, Emkay Research

Exhibit 5: GNPA ratio - Improvement trend stalled in 1Q, but should decelerate, as recoveries accelerate




Source: Company, Emkay Research

Exhibit 2: NIM contracted by 27bps QoQ to 3.3%




Source: Company, Emkay Research

Exhibit 4: Slippages were seasonally elevated



Source: Company, Emkay Research

Exhibit 6: Higher other income, lower opex/LLP led to RoA of >1%



Source: Company, Emkay Research

This report is intended for team.emkay@whitemarguesolutions.com use and downloaded at 08/07/2023 12:30 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Exhibit 7: SBI to report a healthy RoA/RoE trajectory (without factoring-in capital raise)






Exhibit 8: We value the standalone bank at 1.2x Jun-25E ABV and subsidiaries/investments at Rs185 per share



Source: Emkay Research

Source: Emkay Research





Source: Company, Emkay Research

This report is intended for team emkay @whitemarguesolutions.com use and downloaded at 08/07/2023 12:30 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Exhibit 10: Actuals vs Estimates (Q1FY24)

| Rs mn | Actuals | Estir | nates | Vai | iation | Comments |
|------------|---------|---------|-----------|-------|-----------|-------------------------------------------------------------|
| Actual | | Emkay | Consensus | Emkay | Consensus | |
| Net income | 509,683 | 490,379 | 470,422 | 4% | 8% | Lower margins, offset by higher other income, led to a beat |
| PPOP | 252,969 | 232,743 | 233,045 | 9% | 9% | Higher net income and lower opex led to a beat |
| РАТ | 168,843 | 148,737 | 143,915 | 14% | 17% | Lower LLP led to a beat |

Source: Company, Emkay Research

Exhibit 11: Quarterly Summary

| (Rs mn) | 1QFY23 | 2QFY23 | 3QFY23 | 4QFY23 | 1QFY24 | YoY (%) | QoQ (%) | FY23A | FY24E | YoY (%) |
|---------------------------|---------|---------|---------|---------|---------|---------|---------|-----------|-----------|---------|
| Interest Earned | 726,764 | 798,596 | 866,160 | 929,511 | 959,755 | 32 | 3 | 3,321,031 | 4,073,443 | 23 |
| Interest Exp | 414,804 | 446,762 | 485,474 | 525,586 | 570,705 | 38 | 9 | 1,872,626 | 2,445,655 | 31 |
| Net Interest Income | 311,959 | 351,834 | 380,686 | 403,925 | 389,050 | 25 | -4 | 1,448,405 | 1,627,788 | 12 |
| Global NIMs (reported) | 3.02 | 3.32 | 3.50 | 3.60 | 3.33 | 31bps | -27bps | 3.01 | 3.05 | 4bps |
| Non-interest Income | 23,122 | 88,743 | 114,677 | 139,614 | 120,634 | 422 | -14 | 366,156 | 464,202 | 27 |
| Operating Expenses | 207,556 | 229,377 | 243,171 | 297,328 | 256,714 | 24 | -14 | 977,431 | 1,127,048 | 15 |
| Pre Provisioning Profit | 127,526 | 211,200 | 252,193 | 246,211 | 252,969 | 98 | 3 | 837,130 | 964,941 | 15 |
| Provision & Contingencies | 43,924 | 30,387 | 57,606 | 33,157 | 25,013 | -43 | -25 | 165,073 | 135,102 | -18 |
| PBT | 83,602 | 180,814 | 194,587 | 213,054 | 227,956 | 173 | 7 | 672,057 | 829,839 | 23 |
| Income Tax Expense (Gain) | 22,921 | 48,168 | 52,534 | 46,109 | 59,113 | 158 | 28 | 169,732 | 209,120 | 23 |
| Net Profit/(Loss) | 60,681 | 132,645 | 142,053 | 166,945 | 168,843 | 178 | 1 | 502,325 | 620,720 | 24 |
| Gross NPA (%) | 3.91 | 3.52 | 3.14 | 2.78 | 2.76 | -115bps | -2bps | 2.78 | 2.19 | -59bps |
| Net NPA (%) | 1.00 | 0.80 | 0.77 | 0.67 | 0.71 | -29bps | 4bps | 0.67 | 0.56 | -11bps |
| Deposits (Rs bn) | 40,457 | 41,903 | 42,136 | 44,238 | 45,312 | 12 | 2 | 44,238 | 48,986 | 11 |
| Net Advances (Rs bn) | 28,152 | 29,513 | 30,582 | 31,993 | 32,350 | 15 | 1 | 31,993 | 36,169 | 13 |

Source: Company, Emkay Research

Exhibit 12: Revision in Estimates

| Y/E Mar (Rs mn) | FY24E | | | FY25E | | | FY26E | | |
|---------------------|-----------|-----------|--------|-----------|-----------|--------|-----------|-----------|--------|
| | Earlier | Revised | Change | Earlier | Revised | Change | Earlier | Revised | Change |
| Net interest income | 1,667,999 | 1,627,788 | -2.4% | 1,851,097 | 1,807,208 | -2.4% | 2,066,967 | 2,007,968 | -2.9% |
| PPOP | 996,920 | 964,941 | -3.2% | 1,130,093 | 1,078,925 | -4.5% | 1,285,649 | 1,239,190 | -3.6% |
| PAT | 630,987 | 620,720 | -1.6% | 682,583 | 667,687 | -2.2% | 725,135 | 715,389 | -1.3% |
| EPS (Rs) | 70.7 | 69.6 | -1.6% | 76.5 | 74.8 | -2.2% | 81.3 | 80.2 | -1.3% |
| BV (Rs) | 393.2 | 391.5 | -0.4% | 455.2 | 451.3 | -0.8% | 520.9 | 515.5 | -1.0% |

Source: Emkay Research

| Exhibit 13: Key assumption | ons | | | |
|----------------------------|-------|-------|-------|-------|
| (%) | FY23A | FY24E | FY25E | FY26E |
| Loan Growth | 17.0 | 13.1 | 14.4 | 16.0 |
| Deposit Growth | 9.2 | 10.7 | 12.9 | 16.0 |
| NIM | 3.0 | 3.0 | 3.0 | 3.0 |
| GNPA | 2.8 | 2.2 | 1.8 | 1.9 |
| Credit Cost | 0.5 | 0.5 | 0.5 | 0.7 |

Source: Emkay Research

This report is intended for team emkay@whitemarguesolutions.com use and downloaded at 08/07/2023 12:30 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Exhibit 14: Key ratios and trends

| | 1QFY22 | 2QFY22 | 3QFY22 | 4QFY22 | 1QFY23 | 2QFY23 | 3QFY23 | 4QFY23 | 1QFY24 |
|---------------------------------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| Loans (Rs bn) | 24,319 | 24,432 | 25,784 | 27,340 | 28,152 | 29,513 | 30,582 | 31,993 | 32,350 |
| Loan growth (YoY) | 5.8 | 6.5 | 8.9 | 11.6 | 15.8 | 20.8 | 18.6 | 17.0 | 14.9 |
| Loan growth (QoQ) | -0.7 | 0.5 | 5.5 | 6.0 | 3.0 | 4.8 | 3.6 | 4.6 | 1.1 |
| Loan composition (%) | | | | | | | | | |
| Corporate | 32.5 | 31.0 | 30.4 | 31.8 | 31.0 | 31.1 | 30.2 | 30.6 | 30.4 |
| Retail | 35.9 | 37.0 | 36.9 | 36.7 | 36.7 | 36.4 | 36.8 | 36.9 | 37.2 |
| SME | 11.7 | 11.5 | 11.9 | 11.2 | 11.1 | 10.7 | 11.5 | 11.2 | 11.4 |
| Overseas | 15.1 | 15.3 | 15.5 | 15.0 | 16.0 | 16.5 | 15.9 | 15.4 | 14.9 |
| Agri | 4.9 | 5.2 | 5.3 | 5.3 | 5.1 | 5.3 | 5.6 | 5.9 | 6.1 |
| Liability Profile & Margins (%) | | | | | | | | | |
| CASA | 44.6 | 44.8 | 44.2 | 43.8 | 43.7 | 42.9 | 42.7 | 42.1 | 41.2 |
| CA | 6.1 | 6.6 | 5.9 | 6.5 | 5.8 | 5.6 | 5.4 | 6.4 | 5.7 |
| SA | 38.5 | 38.2 | 38.3 | 37.3 | 37.9 | 37.4 | 37.3 | 35.7 | 35.5 |
| Global NIM | 2.92 | 3.09 | 3.11 | 3.12 | 3.02 | 3.32 | 3.50 | 3.60 | 3.33 |
| Domestic NIM | 3.15 | 3.33 | 3.35 | 3.36 | 3.23 | 3.39 | 3.49 | 3.58 | 3.47 |
| Asset Quality | | | | | | | | | |
| GNPA (%) | 5.3 | 4.9 | 4.5 | 4.0 | 3.9 | 3.5 | 3.1 | 2.8 | 2.8 |
| NNPA (%) | 1.7 | 1.5 | 1.3 | 1.0 | 1.0 | 0.8 | 0.8 | 0.7 | 0.7 |
| PCR (%) | 67.9 | 70.1 | 71.2 | 75.0 | 75.1 | 77.9 | 76.1 | 76.4 | 74.8 |
| Slippages (Rs bn) | 163 | 42 | 26 | 36 | 101 | 24 | 32 | 35 | 79 |
| Slippages (%) | 2.8 | 0.7 | 0.4 | 0.6 | 1.7 | 0.4 | 0.5 | 0.5 | 1.1 |
| Capital Adequacy | | | | | | | | | |
| CAR (%) | 13.7 | 13.4 | 13.2 | 13.8 | 13.4 | 13.5 | 13.3 | 14.7 | 14.6 |
| Tier I (%) | 11.4 | 11.0 | 10.9 | 11.4 | 11.2 | 11.1 | 10.8 | 12.1 | 12.0 |
| CET 1 (%) | 9.9 | 10.4 | 10.3 | 9.9 | 9.7 | 9.5 | 9.3 | 10.3 | 10.2 |
| ROE decomposition on total assets (%) | | | | | | | | | |
| NII | 2.4 | 2.7 | 2.6 | 2.5 | 2.5 | 2.8 | 2.9 | 3.0 | 2.8 |
| Other Income (Ex Treasury) | 0.9 | 0.7 | 0.7 | 1.0 | 0.7 | 0.7 | 0.6 | 0.9 | 0.6 |
| Treasury | 0.2 | 0.0 | 0.0 | 0.0 | -0.5 | 0.0 | 0.2 | 0.1 | 0.3 |
| Opex | 1.8 | 2.5 | 1.8 | 1.9 | 1.7 | 1.8 | 1.8 | 2.2 | 1.9 |
| PPOP | 1.7 | 0.9 | 1.6 | 1.6 | 1.0 | 1.7 | 1.9 | 1.8 | 1.8 |
| Provisioning Cost | 0.9 | 0.0 | 0.6 | 0.6 | 0.4 | 0.2 | 0.4 | 0.2 | 0.2 |
| РВТ | 0.8 | 0.9 | 1.0 | 1.0 | 0.7 | 1.4 | 1.5 | 1.6 | 1.6 |
| Tax | 0.2 | 0.2 | 0.3 | 0.3 | 0.2 | 0.4 | 0.4 | 0.3 | 0.4 |
| ROA | 0.6 | 0.7 | 0.7 | 0.7 | 0.5 | 1.0 | 1.1 | 1.2 | 1.2 |
| Leverage (x) | 17.6 | 17.5 | 17.5 | 17.6 | 17.5 | 17.1 | 16.8 | 16.7 | 16.5 |
| ROE | 10.1 | 11.5 | 12.4 | 13.1 | 8.5 | 17.8 | 18.2 | 20.6 | 20.1 |

Source: Company, Emkay Research

This report is intended for team emkay@whitemarquesolutions com use and downloaded at 08/07/2023 12:30 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

State Bank of India: Standalone Financials and Valuations

| Profit & Loss | | | | | |
|----------------------------|-----------|-----------|-----------|-----------|-----------|
| Y/E Mar (Rs mn) | FY22 | FY23 | FY24E | FY25E | FY26E |
| Interest Income | 2,754,573 | 3,321,031 | 4,073,443 | 4,411,358 | 4,813,602 |
| Interest Expense | 1,547,497 | 1,872,626 | 2,445,655 | 2,604,150 | 2,805,633 |
| Net interest income | 1,207,076 | 1,448,405 | 1,627,788 | 1,807,208 | 2,007,968 |
| NII growth (%) | 9.0 | 20.0 | 12.4 | 11.0 | 11.1 |
| Other income | 405,639 | 366,156 | 464,202 | 513,315 | 594,036 |
| Total Income | 1,612,715 | 1,814,561 | 2,091,990 | 2,320,523 | 2,602,005 |
| Operating expenses | 859,792 | 977,431 | 1,127,048 | 1,241,598 | 1,362,815 |
| РРОР | 752,923 | 837,130 | 964,941 | 1,078,925 | 1,239,190 |
| PPOP growth (%) | 5.2 | 11.2 | 15.3 | 11.8 | 14.9 |
| Core PPOP | 720,705 | 850,674 | 898,339 | 1,005,751 | 1,141,007 |
| Provisions & contingencies | 244,521 | 165,073 | 135,102 | 186,295 | 282,787 |
| PBT | 508,402 | 672,057 | 829,839 | 892,630 | 956,402 |
| Extraordinary items | 0 | 0 | 0 | 0 | C |
| Tax expense | 117,459 | 169,732 | 209,120 | 224,943 | 241,013 |
| Minority interest | 0 | 0 | 0 | 0 | C |
| Income from JV/Associates | 0 | 0 | 0 | 0 | C |
| Reported PAT | 390,943 | 502,325 | 620,720 | 667,687 | 715,389 |
| PAT growth (%) | 91.5 | 28.5 | 23.6 | 7.6 | 7.1 |
| Adjusted PAT | 390,943 | 502,325 | 620,720 | 667,687 | 715,389 |
| Diluted EPS (Rs) | 35.5 | 56.3 | 69.6 | 74.8 | 80.2 |
| Diluted EPS growth (%) | 55.2 | 58.6 | 23.6 | 7.6 | 7.1 |
| DPS (Rs) | 7.1 | 11.3 | 14.0 | 15.0 | 16.0 |
| Dividend payout (%) | 16.2 | 20.1 | 20.1 | 20.0 | 20.0 |
| Effective tax rate (%) | 23.1 | 25.3 | 25.2 | 25.2 | 25.2 |
| Net interest margins (%) | 2.8 | 3.0 | 3.0 | 3.0 | 3.0 |
| Cost-income ratio (%) | 53.3 | 53.9 | 53.9 | 53.5 | 52.4 |
| Shares outstanding (mn) | 8,924.6 | 8,924.6 | 8,924.6 | 8,924.6 | 8,924.6 |

| Balance Sheet | | | | | |
|-----------------------------|----------------------------|----------------------------|---------------------|----------------------------|---------------------|
| Y/E Mar (Rs mn) | FY22 | FY23 | FY24E | FY25E | FY26E |
| Share capital | 8,925 | 8,925 | 8,925 | 8,925 | 8,925 |
| Reserves & surplus | 2,791,956 | 3,267,160 | 3,762,935 | 4,296,752 | 4,869,347 |
| Net worth | 2,800,881 | 3,276,085 | 3,771,860 | 4,305,677 | 4,878,271 |
| Deposits | 40,515,341 | 44,237,778 | 48,985,996 | 55,322,073 | 64,156,933 |
| Borrowings | 4,260,434 | 4,931,352 | 5,383,200 | 5,655,864 | 5,475,777 |
| Interest bearing liab. | 44.775.775 | 49.169.129 | 54.369.196 | 60,977,937 | 69.632.711 |
| Other liabilities & prov. | 2,299,318 | 2,724,571 | 3,184,236 | | 4,189,754 |
| Total liabilities & equity | 49 875 974 | 55 169 785 | 61 325 291 | 68,994,215 | 78 700 736 |
| Net advances | 27,339,666 | | 36,168,974 | | |
| Investments | 14,814,455 | 15,703,662 | 16,963,503 | 18,474,729 | 20,415,858 |
| Cash, other balances | 3,945,523 | 3,078,996 | 3,262,152 | 3,658,676 | 4,177,963 |
| Interest earning assets | 46 000 644 | E0 77E 2E1 | E6 204 620 | 63,500,424 | 77 560 274 |
| Fixed assets | 377,082 | 423,818 | 482,201 | 529,307 | 581,049 |
| Other assets | 3,399,249 | 3,970,616 | 4,448,461 | 4,964,484 | 5,550,353 |
| Total assets | | | | | |
| BVPS (Rs) | 49,875,974 287.6 | 55,169,785 336.0 | 61,325,291 391.5 | 68,994,215 451.3 | 78,700,736 515.5 |
| Adj. BVPS (INR) | 264.2 | 318.0 | 374.6 | 433.3 | 492.0 |
| Gross advances | 28,180,239 | | 36,773,221 | | |
| Credit to deposit (%) | 67.5 | 72.3 | 73.8 | 74.8 | 74.8 |
| CASA ratio (%) | 44.5 | 42.7 | 40.5 | 39.9 | 39.9 |
| Cost of deposits (%) | 3.7 | 3.8 | 4.7 | 4.5 | 4.3 |
| Loans-to-Assets (%) | 54.8 | 58.0 | 59.0 | 60.0 | 61.0 |
| Net advances growth (%) | 11.6 | 17.0 | 13.1 | 14.4 | 16.0 |
| Deposit growth (%) | 10.1 | 9.2 | 10.7 | 12.9 | 16.0 |
| Book value growth (%) | 11.5 | 16.8 | 16.5 | 15.3 | 14.2 |
| Source: Company, Emkay Rese | Parch | | | | |

Source: Company, Emkay Research

| Asset quality and oth | er metric | 5 | | | |
|--------------------------|-----------------|-----------|-----------|-----------|-----------|
| Y/E Mar (Rs mn) | FY22 | FY23 | FY24E | FY25E | FY26E |
| Asset quality | | | | | |
| Gross NPLs | 1,120,233. 7 | 909,281.5 | 805,662.1 | 770,073.1 | 933,418.8 |
| Net NPLs | 279,660.9 | 214,667.3 | 201,415.5 | 215,620.5 | 280,025.6 |
| GNPA ratio (%) | 4.0 | 2.8 | 2.2 | 1.8 | 1.9 |
| NNPA ratio (%) | 1.0 | 0.7 | 0.6 | 0.5 | 0.6 |
| Provision coverage (%) | 75.0 | 76.4 | 75.0 | 72.0 | 70.0 |
| Gross slippages | 250,212.3 | 192,230.0 | 246,380.6 | 314,411.0 | 413,345.7 |
| Gross slippage ratio (%) | 0.9 | 0.6 | 0.7 | 0.8 | 0.9 |
| LLP ratio (%) | 0.7 | 0.5 | 0.5 | 0.5 | 0.7 |
| NNPA to networth (%) | 10.1 | 6.6 | 5.3 | 5.0 | 5.7 |
| Capital adequacy | | | | | |
| Total CAR (%) | 13.8 | 14.7 | 14.2 | 13.6 | 12.8 |
| Tier-1 (%) | 11.4 | 12.1 | 11.9 | 11.6 | 11.1 |
| CET-1 (%) | 9.9 | 10.3 | 10.3 | 10.2 | 9.9 |
| RWA-to-Total Assets (%) | 55.0 | 50.5 | 53.0 | 55.0 | 57.0 |
| Miscellaneous | | | | | |
| Total income growth (%) | 2.4 | 16.7 | 23.1 | 8.5 | 9.8 |
| Opex growth (%) | 4.0 | 13.7 | 15.3 | 10.2 | 9.8 |
| Core PPOP growth (%) | 10.0 | 18.0 | 5.6 | 12.0 | 13.4 |
| PPOP margin (%) | 23.8 | 22.7 | 21.3 | 21.9 | 22.9 |
| PAT/PPOP (%) | 51.9 | 60.0 | 64.3 | 61.9 | 57.7 |
| LLP-to-Core PPOP (%) | 33.9 | 19.4 | 15.0 | 18.5 | 24.8 |
| Yield on advances (%) | 6.7 | 7.5 | 8.5 | 8.1 | 7.8 |
| Cost of funds (%) | 3.6 | 4.0 | 4.7 | 4.5 | 4.3 |

Source: Company, Emkay Research

| Valuations and key Ratios | | | | | | | | |
|---------------------------|---------|---------|---------|---------|---------|--|--|--|
| Y/E Mar | FY22 | FY23 | FY24E | FY25E | FY26E | | | |
| P/E (x) | 8.8 | 6.9 | 5.6 | 5.2 | 4.8 | | | |
| P/B (x) | 1.4 | 1.2 | 1.0 | 0.9 | 0.8 | | | |
| P/ABV (x) | 1.6 | 1.3 | 1.1 | 0.9 | 0.8 | | | |
| P/PPOP (x) | 2.2 | 2.0 | 1.7 | 1.5 | 1.3 | | | |
| Dividend yield (%) | 1.2 | 2.0 | 2.4 | 2.6 | 2.8 | | | |
| DuPont-RoE split (%) | | | | | | | | |
| NII/avg assets | 2.5 | 2.8 | 2.8 | 2.8 | 2.7 | | | |
| Other income | 0.9 | 0.7 | 0.8 | 0.8 | 0.8 | | | |
| Fee income | 2.0 | 1.2 | 1.2 | 1.2 | 1.1 | | | |
| Opex | 1.8 | 1.9 | 1.9 | 1.9 | 1.8 | | | |
| PPOP | 1.6 | 1.6 | 1.7 | 1.7 | 1.7 | | | |
| Core PPOP | 1.5 | 1.6 | 1.5 | 1.5 | 1.5 | | | |
| Provisions | 0.5 | 0.3 | 0.2 | 0.3 | 0.4 | | | |
| Tax expense | 0.2 | 0.3 | 0.4 | 0.3 | 0.3 | | | |
| RoA (%) | 0.8 | 1.0 | 1.1 | 1.0 | 1.0 | | | |
| Leverage ratio (x) | 19.6 | 18.9 | 17.9 | 17.3 | 17.1 | | | |
| RoE (%) | 16.1 | 18.1 | 19.1 | 17.8 | 16.6 | | | |
| Quarterly data | | | | | | | | |
| Rs mn, Y/E Mar | Q1FY23 | Q2FY23 | Q3FY23 | Q4FY23 | Q1FY24 | | | |
| NII | 311,959 | 351,834 | 380,686 | 403,925 | 389,050 | | | |
| NIM(%) | 3.0 | 3.3 | 3.5 | 3.6 | 3.3 | | | |
| PPOP | 127,526 | 211,200 | 252,193 | 246,211 | 252,969 | | | |
| PAT | 60,681 | 132,645 | 142,053 | 166,945 | 168,843 | | | |
| EPS (Rs) | 6.80 | 14.86 | 15.92 | 18.71 | 18.92 | | | |

Source: Company, Emkay Research

Source: Company, Emkay Research

This report is intended for team emkay @ whitemarguesolutions.com use and downloaded at 08/07/2023 12:30 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

RECOMMENDATION HISTORY - DETAILS

| Date | CMP (INR) | TP (INR) | Rating | Analyst |
|-----------|-----------|----------|--------|------------|
| 19-May-23 | 575 | 700 | Buy | Anand Dama |
| 09-Mar-23 | 559 | 715 | Buy | Anand Dama |
| 04-Feb-23 | 544 | 715 | Buy | Anand Dama |
| 05-Nov-22 | 594 | 715 | Buy | Anand Dama |
| 06-Aug-22 | 531 | 640 | Buy | Anand Dama |
| 15-May-22 | 445 | 640 | Buy | Anand Dama |
| 24-Mar-22 | 487 | 680 | Buy | Anand Dama |
| 06-Feb-22 | 530 | 680 | Buy | Anand Dama |
| 03-Nov-21 | 528 | 680 | Buy | Anand Dama |
| 05-Jul-21 | 433 | 600 | Buy | Anand Dama |
| 23-May-21 | 401 | 600 | Buy | Anand Dama |
| 05-Feb-21 | 393 | 460 | Buy | Anand Dama |
| 20-Jan-21 | 303 | 340 | Buy | Anand Dama |
| 03-Jan-21 | 279 | 340 | Buy | Anand Dama |
| 05-Nov-20 | 219 | 265 | Buy | Anand Dama |

RECOMMENDATION HISTORY - TREND



Source: Bloomberg, Company, Emkay Research

Source: Company, Emkay Research

This report is intended for team emkay@whitemarguesolutions.com use and downloaded at 08/07/2023 12:30 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO->.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India, EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits, Details of associates are available on our website i.e. www.emkavglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkavglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

bis report is intended for team emkay @ whitemarguesolutions com use and downloaded at 08/07/2023 12:30 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for gualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in 1 the securities recommended in this report as of August 5, 2023
- GFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report 2. Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report 3. during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities 4. recommended in this report as of August 5, 2023
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject 5 company at the end of the month immediately preceding the August 5, 2023
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months. 6.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for 7 investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 8. EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

| Ratings | Expected Return within the next 12-18 months. | |
|---------|-----------------------------------------------|--|
| BUY | Over 15% | |
| HOLD | Between -5% to 15% | |
| SELL | Below -5% | |

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

bis report is intended for team emkay @ whitemarguesolutions com use and downloaded at 08/07/2023 12:30 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates for the subject company in the past twelve months.